晚期非小细胞肺癌3种化疗方案的药物经济学评价(2)
 |
| 第1页 |
参见附件。
[4]费小非,汤致强.晚期非小细胞肺癌四种化疗方案的成本—效果分析[J].中国药事,2007,21(03):204-207.
[5]王宇,盛明宇,汤致强.不同化疗方案治疗晚期非小细胞肺癌成本-效果分析[J].中国医院用药评价与分析,2007,7(01):52-54.
[6]Amr S, Abu Lila,Tomoko, Okada,Yusuke, Doi,Masako, Ichihara,Tatsuhiro, Ishida,Hiroshi, Kiwada . Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism[J].International journal of pharmaceutics,2012,426(1-2): 263-270.
[7]T, Mazard,M, Ychou,S, Thezenas,S, Poujol,F, Pinguet,A, Thirion,J P, Bleuse,F, Portales,E, Samalin,E, Assenat . Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX[J].Cancer chemotherapy and pharmacology,2012,69(3):807-814.
[8]刘玉媛,尹明兰.治疗晚期非小细胞肺癌3种化疗方案的成本-效果分析[J].中国药房,2005,16(06):439-440.
[9]陈彦清.晚期非小细胞肺癌3种化疗方案的成本-效果分析[J].中国药业,2007,16(07):29-30.
[10]卢火木,朱世权,杜芳琼.3种化疗方案治疗非小细胞肺癌的成本-效果分析[J].海峡药学,2009,21(07):180-181.
您现在查看是摘要介绍页，详见PDF附件。